Reata Pharmaceuticals

YTD

ALL

Why Robinhood?

You can watch RETA and buy or sell other stocks, ETFs, and their options commission-free!

About RETA

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

CEO

J. Warren Huff

CEOJ. Warren Huff

Employees

—

Employees—

Headquarters

Plano, Texas

HeadquartersPlano, Texas

Founded

2002

Founded2002

Employees

—

Employees—

RETA Key Statistics

Market cap

6.57B

Market cap6.57B

Price-Earnings ratio

-57.67

Price-Earnings ratio-57.67

Dividend yield

—

Dividend yield—

Average volume

610.38K

Average volume610.38K

High today

—

High today—

Low today

—

Low today—

Open price

—

Open price—

Volume

0.00

Volume0.00

52 Week high

$172.46

52 Week high$172.46

52 Week low

$21.83

52 Week low$21.83

People also own

Based on the portfolios of people who own RETA. This list is generated using Robinhood data, and it’s not a recommendation.